New approach aims to make advanced myeloma treatment safer at home
NCT ID NCT06421675
Summary
This study is testing whether a different dosing schedule for the drug elranatamab can make treatment safer and allow patients with advanced multiple myeloma to receive it as outpatients. The trial involves 40 patients whose cancer has returned or stopped responding to at least three previous types of treatment. Researchers will monitor hospitalization rates and serious infections to see if this new approach improves treatment tolerability.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Juravinski Cancer Center
RECRUITINGHamilton, Ontario, L8V 1C3, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
London Health Science Centre - Victoria Hospital
NOT_YET_RECRUITINGLondon, Ontario, N6A 5W9, Canada
-
Ottawa Hospital
RECRUITINGOttawa, Ontario, K1H 8L6, Canada
Contact Phone: •••-•••-••••
-
Vancouver Cancer Center
RECRUITINGVancouver, British Columbia, V5Z 1L3, Canada
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.